{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Xu S"],"pubmed_abstract":["<h4>Objective</h4>This study aimed to investigate hepatitis B virus (HBV) reactivation and its impact on postoperative survival in patients with HBV-related hepatocellular carcinoma (HCC) who underwent conversion therapy. The therapeutic regimen consisted of interventional procedures (hepatic artery infusion chemotherapy [HAIC] and/or transarterial chemoembolization [TACE]) combined with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs).<h4>Methods</h4>A retrospective analysis was performed at a single institution involving 91 patients <i>who had</i> initially unresectable HCC linked to the hepatitis B virus. These patients achieved resectability following conversion therapy and subsequently underwent surgical tumor removal. Logistic regression identified risk facto"],"journal":["Frontiers in cellular and infection microbiology"],"pagination":["1598193"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12310596"],"repository":["biostudies-literature"],"pubmed_title":["Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors."],"pmcid":["PMC12310596"],"pubmed_authors":["Yuan D","Wei M","Bai T","Tang Z","Pang Q","Xu S","Wang X","Liu D","Wu F"],"additional_accession":[]},"is_claimable":false,"name":"Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors.","description":"<h4>Objective</h4>This study aimed to investigate hepatitis B virus (HBV) reactivation and its impact on postoperative survival in patients with HBV-related hepatocellular carcinoma (HCC) who underwent conversion therapy. The therapeutic regimen consisted of interventional procedures (hepatic artery infusion chemotherapy [HAIC] and/or transarterial chemoembolization [TACE]) combined with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs).<h4>Methods</h4>A retrospective analysis was performed at a single institution involving 91 patients <i>who had</i> initially unresectable HCC linked to the hepatitis B virus. These patients achieved resectability following conversion therapy and subsequently underwent surgical tumor removal. Logistic regression identified risk facto","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-03-18T13:31:38.184Z","creation":"2025-08-18T09:54:03.347Z"},"accession":"S-EPMC12310596","cross_references":{"pubmed":["40746957"],"doi":["10.3389/fcimb.2025.1598193"]}}